Larimar Therapeutics Announces $70 Million Underwritten Offering
Learimar Therapeutics (Nasdaq: LRMR) announced an underwritten offering of 22,225,000 shares at $3.15 per share, aligned with the previous day's closing price. The total expected gross proceeds are approximately $70 million, slated to close around September 16, 2022. The funds will support the clinical development of CTI-1601 and general corporate purposes. Notable investors, including Deerfield Management, participated in this offering, with Guggenheim Securities as the lead manager.
- Offering expected gross proceeds of approximately $70 million.
- Funds will support the clinical development of CTI-1601.
- None.
BALA CYNWYD, Pa., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar” or the “Company”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of an underwritten offering of 22,225,000 shares of common stock. The shares are being sold at an offering price of
Deerfield Management and other notable life science investors participated in the offering.
Guggenheim Securities, LLC is acting as lead book-running manager for the offering and William Blair & Company, L.L.C. is also acting as a book-runner for the offering. LifeSci Capital LLC and JMP Securities, a Citizens Company, are acting as co-managers for the offering.
Larimar intends to use the net proceeds from the offering to support the clinical development of CTI-1601, and for working capital and general corporate purposes, including research and development expenses.
A shelf registration statement on Form S-3 (File No. 333-246370) relating to the offering of the shares of common stock described above was filed with the Securities and Exchange Commission (the “SEC”) and became effective on September 1, 2020. A prospectus supplement relating to the offering, and the accompanying prospectus, will be filed with the SEC. When available, copies of the prospectus supplement and accompanying prospectus may also be obtained from the offices of Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison, 8th Floor, New York, NY 10017, via telephone at (212) 518-9544 or via email at GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Larimar Therapeutics
Larimar Therapeutics, Inc. (Nasdaq: LRMR), is a clinical-stage biotechnology company focused on developing treatments for complex rare diseases. Larimar’s lead compound, CTI-1601, is being developed as a potential treatment for Friedreich's ataxia. Larimar also plans to use its intracellular delivery platform to design other fusion proteins to target additional rare diseases characterized by deficiencies in intracellular bioactive compounds.
Forward-Looking Statements
Any statements in this press release about future expectations, plans and prospects for the Company, including the Company’s expectations regarding the completion of the offering, the Company’s use of those proceeds, the underwriters’ exercise of their overallotment option to purchase additional shares of common stock and other statements containing the words “anticipate,” “believe,” “estimate,” “upcoming,” “plan,” “target”, “intend,” “expect” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, risks and uncertainties related to market conditions and the satisfaction of customary closing conditions related to the offering, and other risks and uncertainties related to the offering, as well as the risks and uncertainties set forth in the “Risk Factors” section and elsewhere in the prospectus supplement related to the offering filed with the SEC and in the other filings made by the Company with the SEC, including but not limited to the Company’s periodic reports, including the Company’s most recent annual report on Form 10-K, subsequent quarterly reports on Form 10-Q and current reports on Form 8-K, filed with or furnished to the SEC and available at www.sec.gov. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date of this press release. Important factors could cause our actual results to differ materially from those indicated or implied by forward-looking statements, and as such we anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.
Investor Contact:
Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com
(212) 915-2569
Company Contact:
Michael Celano
Chief Financial Officer
mcelano@larimartx.com
(484) 414-2715
FAQ
What is the stock symbol for Larimar Therapeutics?
When is the closing date for Larimar's stock offering?
How much is Larimar's stock offering expected to raise?
What will Larimar do with the proceeds from the stock offering?
Who are the lead underwriters for Larimar's offering?
